First-in-human testing of a mutant KRAS vaccine for pancreatic cancer interception in high-risk cohorts
Saurav D. Haldar(Broad Institute), Neeha Zaidi(Johns Hopkins University), Marina Baretti(Sidney Kimmel Comprehensive Cancer Center), Hejia Wang(Bloomberg (United States)), Christopher J. Thoburn(Johns Hopkins University), Daniel A. Laheru(Bloomberg (United States)), Hassan Sinan(Icahn School of Medicine at Mount Sinai), Nancy Sun(Cedars-Sinai Medical Center), Elizabeth Abou Diwan(Johns Hopkins University), Won Jin Ho(Johns Hopkins University), Elizabeth M. Jaffee(Bloomberg (United States)), Dimitrios N. Sidiropoulos(Johns Hopkins University), Jiayun Lu(Bloomberg (United States)), Nilofer S. Azad(Johns Hopkins Hospital), Maureen Berg(Johns Hopkins University), Linda C. Chu(Johns Hopkins University), Mark Yarchoan(Sidney Kimmel Comprehensive Cancer Center), Luciane T. Kagohara(Bloomberg (United States)), Katherine M. Bever(Sidney Kimmel Comprehensive Cancer Center), Michael Goggins(Johns Hopkins University), Hao Wang(The University of Sydney), Takeichi Yoshida(Johns Hopkins University), Anna Ferguson(Johns Hopkins University), Amy M. Thomas(Johns Hopkins University), Julie M. Nauroth(Johns Hopkins University), Matthew Guo(Johns Hopkins University), Zirui Zhu(Johns Hopkins University), Amanda L. Huff(Johns Hopkins University)
Cited by 1
Related Papers
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
|New England Journal of Medicine|2015|9.4k
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
|Science Translational Medicine|2014|5.1k